- Primary endpoint met (p
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
On 6ix: 6ix.com/news/mirum-pharmaceuticals-announces-positive-phase-3-restore-study-results-evaluating
Watch Mirum Pharmaceuticals' latest callMirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings CallMirum Pharmaceuticals, Inc. on 6ix
Story so far
- Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
- Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
Earlier from Mirum Pharmaceuticals
- Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
- Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
- Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
- Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
- Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Later from Mirum Pharmaceuticals
- Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
- Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
- Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
- Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals